HCW Biologics is trading $2.82 (+11.76%) with no verified company-specific announcement dated August 18, 2026 explaining the advance.
- The latest confirmed filing was the August 14, 2026 quarterly-results report.
- Results showed continued liquidity pressure, including a widened $5.2 million net loss and a $1.6 million private placement.
- The broader market was lower; speculative trading or a technical rebound may be involved, but this remains unconfirmed.